Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has scheduled its Q2 2025 financial results conference call for Friday, August 15th, 2025, at 8:00 AM ET.
The call will discuss Q2 2025 financial performance, corporate progress, and other developments. Investors can access the call via phone (U.S. toll-free: 888-506-0062; International: +1 973-528-0011; Access code: 470429) or webcast. A replay will be available through August 29th, 2025.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of healthcare industry experience, notably as Founder of TEN20 Medical Distribution and executive positions at Stryker Imaging and Brainlab.
The appointment comes at a crucial time as MLSS advances the commercial rollout of its CompuFlo® Epidural System, which recently received Medicare Part B payment rates under CPT® code 0777T. The company is also expanding its dental segment through the STA Single Tooth Anesthesia® System. Papes will be instrumental in scaling both platforms and implementing market access strategies.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Eric C. Hines as its new Chief Executive Officer. Hines brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, most recently serving as President of North America at Ex Libris where he doubled annual revenue from $50M to $100M.
The appointment comes at a crucial time as Milestone Scientific advances its CompuFlo® technology, having secured Medicare Part B payment rates under CPT® code 0777T and initial commercial insurance payments. Hines' experience in healthcare and track record of commercial expansion positions him to drive adoption of the company's technology in medical and dental markets while pursuing new clinical indications and global opportunities.
Milestone Scientific (NYSE:MLSS) has announced the commercial launch of its CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey. The center is led by Dr. Chi-Shin Jason Chiu, a double board-certified physician in Pain Management and Anesthesiology.
The CompuFlo system leverages the company's proprietary DPS Dynamic Pressure Sensing® technology, providing real-time feedback for accurate epidural space identification. Clinical studies have demonstrated the system's ability to reduce false loss of resistance, minimize complications, and improve epidural procedure success rates.
This deployment is part of Milestone Scientific's broader strategy to expand the adoption of CompuFlo across U.S. and international markets.
Milestone Scientific (NYSE: MLSS) has appointed Shanth Thiyagalingam to its Board of Directors, effective May 14, 2025. Thiyagalingam, currently CEO of PainTEQ, brings over 20 years of global leadership experience in medical devices and pharmaceuticals. This strategic appointment supports Milestone's expansion of its CompuFlo® Epidural System, particularly following recent favorable Medicare Part B payment rates for CPT code 0777T and FSS contract award.
At PainTEQ, Thiyagalingam led the company's growth from startup to market innovator, securing a Category 1 CPT code for the LinQ procedure. His extensive experience includes leadership roles at Abbott, where he managed APAC Neuromodulation operations, Nevro, Stryker, and St. Jude Medical. He holds a Bachelor of Medical Science, Master's in Marketing Management, and MBA.
Milestone Scientific (NYSE: MLSS) reported financial results for 2024, showing revenue of $8.6 million, down from $9.8 million in 2023. Despite the revenue decline, the company highlighted positive developments including Medicare reimbursement expansion for its CompuFlo® Epidural System across multiple U.S. states and a Federal Supply Schedule contract.
The company's U.S. e-commerce platform for dental products generated $5.1 million in revenue, up from $4.8 million in 2023. International revenue decreased to $3.4 million. Gross profit was $6.4 million, down from $6.8 million in 2023. Operating loss improved to $6.8 million from $7.1 million, while net loss decreased to $4.7 million ($0.06 per share) from $6.9 million ($0.10 per share) in 2023.
The company ended 2024 with $3.3 million in cash, $5.5 million in working capital, and no debt, while reporting strong Q1 2025 initial performance and positive outlook.
Milestone Scientific (NYSE: MLSS) has announced that InfiniSurg, , a New Jersey-based ambulatory surgery center, has adopted its CompuFlo® Epidural System for clinical practice. The system will be operated by Dr. Roman Kosiborod, DO, who brings over 20 years of experience in interventional pain management and ambulatory anesthesia.
The order was received through Milestone's distributor, Axial Biologics. The CompuFlo® system utilizes Dynamic Pressure Sensing Technology® to precisely identify the epidural space, providing real-time visual and audible feedback during needle placement. This technology aims to reduce complications such as dural puncture while improving procedural efficiency and patient safety.
Milestone Scientific (NYSE: MLSS) announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical , following a successful evaluation by Dr. Ilana Etelzon. The system, which employs proprietary Dynamic Pressure Sensing Technology®, provides real-time verification of epidural needle placement to enhance patient safety and procedural efficiency.
The implementation follows the recent Medicare price assignment for the CompuFlo® system, which is helping drive broader accessibility across interventional pain management centers. The technology offers real-time feedback for needle placement confirmation, improving procedural accuracy and safety in pain management procedures.
Milestone Scientific (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, following a successful pilot program with Dr. Varinder Dhillon. The implementation takes place at SurgiCore Montvale, one of 12 SurgiCore centers in the NY/NJ metro area, suggesting potential for network expansion.
The company reports increasing adoption of the system following a recent Medicare price assignment. The CompuFlo® Epidural System, powered by Dynamic Pressure Sensing Technology®, provides real-time feedback for accurate needle placement during epidural procedures, reducing complications associated with traditional techniques.
Dr. Dhillon praised the system's precision and reliability in improving patient care and procedural efficiency. Neal Goldman, Chairman and Interim CEO, highlighted the growing traction within the healthcare community, particularly among pain management clinics nationwide following the Medicare price assignment.